UKPDS 34: Metformin vs Conventional Glycemic Control on Outcomes

Slides:

Advertisements

Similar presentations

Diabetes Mellitus Type 2

Advertisements

Canadian Diabetes Association 2013 Clinical Practice Guidelines Targets for Glycemic Control Chapter 8 S. Ali Imran, Rémi Rabasa-Lhoret, Stuart Ross.

The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.

Dr. A. K. Singh M.D (Medicine), D.M (Endocrinology)

Recommendation In people with clinical cardiovascular disease in whom glycemic targets are not met, a SGLT2 inhibitor with demonstrated cardiovascular.

Recent Breakthroughs in Cardiovascular Outcomes Trials in T2DM

Disclosure Consultations and Honoraria Grant Support

Cardiovascular Outcomes Trials in Diabetes: The Truth, the Whole Truth, and Nothing But the Truth.

SAVOR-TIMI 53 Summary SAVOR-TIMI 53: Primary End Point of CV Death, MI, Ischemic Stroke.

Diabetes and Risk of CV Outcomes

Panelists. Type 2 Diabetes, Renal Impairment, and CHD: Reducing 2 Vascular Risks With 1 Stone.

CV Risk reduction in T2DM with GLP-1 Agonists: Should We Change Our Clinical Practice?

Updates on Emerging GLP-1 Receptor Agonists

Thrombosis, Cancer, and NOACs

Global Projections for Diabetes:

Patient Case Discussions in T2D: What Intensification Plan Is Best?

SGLT2 Inhibitors in Phase 3 Trials

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Beta-Cell Classification of Diabetes and the Egregious Eleven: Logic for Newer Algorithms/ Processes of Care The Role of Newer Anti-Diabetes Medications.

Early Type 2 Diabetes Mellitus: A Cardiovascular Disease

Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.

Optimizing Patient Outcomes in IBD

Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population

Latest Cardiovascular Outcomes Trials: A Closer Look at the LEADER Results.

CV Outcome Studies Empa-reg Leader Pio Stroke (Proactive) Bromocriptine Metformin-UKPDS.

T2DM and CV Outcomes Trials: A Deep Dive!

ADA/EASD Position Statement: Approach to Hyperglycemia Management

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Treatment Options to Consider

SGLT2 inhibitors, Now Part of the Cardiology Toolkit for Comprehensive CV Risk Management.

A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.

Integrated Diabetes Care: How Can We Make the Best Use of New Technology?

Growing Diabetes Pandemic Worldwide

Tackling CV Risk in T2DM.

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

EXAMINE Study: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome.

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.

Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?

Type 2 Diabetes Management: Where Are We Heading in Our Efforts to Control CV Risk?

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

LEADER One Year On.

GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?

Learning Objectives Metabolic Abnormalities Associated With T2D.

Antihyperglycemic Therapy

Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

Managing CKD-Associated Anemia in Challenging Patients

T2DM, CV Risk, and Modulating Risk With Glucose-Lowering Strategies

CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?

A Case Challenge.

Oral Combination Therapy for T2D

Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.

Pharmacotherapy for Diabetic Coronary Disease:

Typical Patient Presentation

Insulin in Diabetes Management: Effective Patient Selection Is Key

Add-On Therapy to Insulin in T1DM Management

Patient Selection for Modern T2D Agents

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?

2015 EASD In Review: CV Risk management in t2dm

DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.

Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

New Approaches for Type 2 Diabetes -- GLP-1 RAs Now and in the Future

Oral Antihyperglycemic Agents In the UKPDS, developed glycemic dominance, irrespective of the factor utilized (metformin, sulfonylureas, or insulin)

John J.V. McMurray et al. JCHF 2018;6:8-17

BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

CKD Is a Global Burden With Major Implications

The Elevated Role of GLP-1 RAs in Diabetes Management: Which Patients Should We Aim For?

Presentation transcript:

Pathophysiologic Mechanisms Leading to the Development of Hyperglycemia

UKPDS 34: Metformin vs Conventional Glycemic Control on Outcomes

Metformin Use in T2DM Patients With CKD

Newer Oral Pharmacologic Options for the Management of Hyperglycemia

VERIFY: Vildagliptin and Metformin Early Initiation vs Standard Metformin Initiation

Notable Side Effects With Oral Antihyperglycemic Agents

SAVOR-TIMI 53: Mortality and CV Outcomes

Notable Side Effects With Oral Antihyperglycemic Agents (cont)

ABCD Management of T2DM: A Personalized Approach